U.S. Markets close in 4 hrs 8 mins

Myovant Sciences Ltd. (MYOV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
24.72+0.49 (+2.02%)
As of 11:51AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.23
Bid24.59 x 1200
Ask24.70 x 800
Day's Range23.36 - 25.03
52 Week Range5.98 - 25.03
Avg. Volume1,150,806
Market Cap2.239B
Beta (5Y Monthly)2.58
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Breakeven On The Horizon For Myovant Sciences Ltd. (NYSE:MYOV)
    Simply Wall St.

    Breakeven On The Horizon For Myovant Sciences Ltd. (NYSE:MYOV)

    We feel now is a pretty good time to analyse Myovant Sciences Ltd.'s (NYSE:MYOV) business as it appears the company...

  • Benzinga

    Recap: Myovant Sciences Q2 Earnings

    Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), which missed the estimate of ($0.73).Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $290,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Myovant Sciences hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 12, 2020View more earnings on MYOVTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/mkxeraxuTechnicals Company's 52-week high was at $23.04Company's 52-week low was at $5.39Price action over last quarter: down 0.84%Company Profile Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 12, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • How to Catch a Falling Knife

    How to Catch a Falling Knife

    This refers to the situation where a stock is making a very quick and sizable drop and appears to be a good value. The logic of the warning is that it just isn't possible to know how far a stock might drop before it eventually finds support and it is easy to bury yourself when your timing is off.